Evidence map›Paper›PMID 34925507›Full record

ArticleJournal of oncology2021

Morbidity, Prognostic Factors, and Competing Risk Nomogram for Combined Hepatocellular-Cholangiocarcinoma.

Xiaoyuan Chen, Yiwei Lu, Xiaoli Shi, Xuejiao Chen, Dawei Rong, Guoyong Han, Long Zhang, Chuangye Ni, Jie Zhao, Yun Gao and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Xiaoyuan ChenSchool of Medicine, Southeast University, Nanjing, China.ORCID https://orcid.org/0000-0003-0804-385X
Yiwei LuHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Xiaoli ShiSchool of Medicine, Southeast University, Nanjing, China.
Xuejiao ChenHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Dawei RongSchool of Medicine, Southeast University, Nanjing, China.
Guoyong HanHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Long ZhangHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Chuangye NiHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jie ZhaoHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yun GaoHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.ORCID https://orcid.org/0000-0003-4161-1695
Xuehao WangSchool of Medicine, Southeast University, Nanjing, China.ORCID https://orcid.org/0000-0002-6050-3385
Chinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCombined hepatocellular-cholangiocarcinoma (CHC) is a rare and heterogeneous histological subtype of primary liver cancer, which is still poorly understood. This study aimed to describe the epidemiological and clinical features, investigate the prognostic indicators, and develop a competing risk nomogram for CHC.

methodsThe study cohort was taken from the Surveillance, Epidemiology, and End Results database. The annual percent change (APC) in incidence was calculated using the joinpoint regression. The nomogram was developed based on multivariate competing risk survival analyses and validated by calibration curves. Akaike information criterion, Bayesian information criterion, Harrell's C-index, and area under the receiver operating characteristic curves were obtained to compare prognostic performance. Decision curve analysis was introduced to examine the clinical value of the models.

resultsThe overall incidence of CHC was 0.062 per 100,000 individuals in 2004 and 0.081 per 100,000 individuals in 2018, with an APC of 1.0% (

conclusionThe morbidity of CHC remained stable between 2004 and 2018. The constructed nomogram could predict the prognosis with good performance, which was meaningful to individual treatment strategies optimization. CHC patients should also be considered as potential liver transplantation recipients, especially those within the Milan Criteria, but the finding still needs more evidence to be further confirmed.

Identifiers

PMID34925507
PMCPMC8683178
OpenAlexW4200168010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.